A Concise Review on Tyrosine Kinase Targeted Cancer Therapy

被引:0
作者
Shah, Ashish [1 ]
Patel, Chhagan [2 ]
Parmar, Ghanshaym [1 ]
Patel, Ashish [3 ]
Jain, Manav [4 ]
机构
[1] Sumandeep Vidyapeeth, Dept Pharm, Vadodara, Gujarat, India
[2] Shree Sarvajaink Pharm Coll, Mehsana, Gujarat, India
[3] CHARUSAT, Ramanbhai Patel Coll Pharm, Anand, Gujarat, India
[4] Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh, Punjab, India
关键词
Tyrosine kinase; types of receptors; tyrosine kinase inhibitors; cancer; small molecules; targeted therapy; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER; SRC FAMILY KINASES; OPEN-LABEL; BREAST-CANCER; DOUBLE-BLIND; 1ST-LINE TREATMENT; MOLECULAR TARGETS; THYROID-CANCER;
D O I
10.2174/1574885517666220331104025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tyrosine Kinase (TK) is considered one of the important family members of the kinase family due to its important role in various cellular processes like cell growth, cell differentiation, apoptosis, etc. Mutation, overexpression, and dysfunction of tyrosine kinase receptors lead to the development of malignancy; thus, they are considered one of the important targets for the development of anti-cancer molecules. The tyrosine kinase family is majorly divided into two classes; receptor and non-receptor tyrosine kinase. Both of the classes have an important role in the development of tumour cells. Currently, more than 40 FDA-approved tyrosine kinase inhibitors are used to treat various types of cancers. Tyrosine kinase inhibitors mainly block the phosphorylation of tyrosine residue of the corresponding kinase substrate, so activation of downstream signalling pathways can be inhibited. The promising results of tyrosine kinase inhibitors in solid tumours have revolutionized oncology research. In this article, we summarized the role of some important members of the tyrosine kinase family in the development and progression of tumour cells and the significance of tyrosine kinase inhibitors in the treatment of various types of cancer.
引用
收藏
页码:96 / 107
页数:12
相关论文
共 118 条
  • [31] Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli
    Galisteo, Maria L.
    Yang, Yan
    Urena, Jesus
    Schlessinger, Joseph
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (26) : 9796 - 9801
  • [32] FAK family kinases: The Yin and Yang of cancer cell invasiveness
    Genna, Alessandro
    Gil-Henn, Hava
    [J]. MOLECULAR & CELLULAR ONCOLOGY, 2018, 5 (04):
  • [33] Anticancer drug targets: growth factors and growth factor signaling
    Gibbs, JB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) : 9 - 13
  • [34] Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
    Gocek, Elzbieta
    Moulas, Anargyros N.
    Studzinski, George P.
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2014, 51 (03) : 125 - 137
  • [35] The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia:: implications for diagnosis, classification, and management
    Gotlib, J
    Cools, J
    Malone, JM
    Schrier, SL
    Gilliland, DG
    Coutré, SE
    [J]. BLOOD, 2004, 103 (08) : 2879 - 2891
  • [36] Role of ABL family kinases in cancer: from leukaemia to solid tumours
    Greuber, Emileigh K.
    Smith-Pearson, Pameeka
    Wang, Jun
    Pendergast, Ann Marie
    [J]. NATURE REVIEWS CANCER, 2013, 13 (08) : 559 - 571
  • [37] Fibroblast growth factor signaling in tumorigenesis
    Grose, R
    Dickson, C
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (02) : 179 - 186
  • [38] Selumetinib in Children with Inoperable Plexiform Neurofibromas
    Gross, Andrea M.
    Wolters, Pamela L.
    Dombi, Eva
    Baldwin, Andrea
    Whitcomb, Patricia
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Bornhorst, Miriam
    Shah, Amish C.
    Martin, Staci
    Roderick, Marie C.
    Pichard, Dominique C.
    Carbonell, Amanda
    Paul, Scott M.
    Therrien, Janet
    Kapustina, Oxana
    Heisey, Kara
    Clapp, D. Wade
    Zhang, Chi
    Peer, Cody J.
    Figg, William D.
    Smith, Malcolm
    Glod, John
    Blakeley, Jaishri O.
    Steinberg, Seth M.
    Venzon, David J.
    Doyle, L. Austin
    Widemann, Brigitte C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (15) : 1430 - 1442
  • [39] Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    Grothey, Axel
    Van Cutsem, Eric
    Sobrero, Alberto
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Barone, Carlo
    Adenis, Antoine
    Tabernero, Josep
    Yoshino, Takayuki
    Lenz, Heinz-Josef
    Goldberg, Richard M.
    Sargent, Daniel J.
    Cihon, Frank
    Cupit, Lisa
    Wagner, Andrea
    Laurent, Dirk
    [J]. LANCET, 2013, 381 (9863) : 303 - 312
  • [40] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
    Han, Baohui
    Li, Kai
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Zhao, Yizhuo
    Yu, Hao
    Zhao, Yang
    Chen, Weiqiang
    Luo, Yi
    Wu, Lin
    Wang, Xiuwen
    Pirker, Robert
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Sun, Yan
    [J]. JAMA ONCOLOGY, 2018, 4 (11) : 1569 - 1575